Patents by Inventor Andreas Evers

Andreas Evers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS
    Publication number: 20160220643
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 4, 2016
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart
  • EXENDIN-4 PEPTIDE ANALOGUES AS DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS
    Publication number: 20160168225
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake
    Type: Application
    Filed: December 12, 2014
    Publication date: June 16, 2016
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart, Dieter Kadereit
  • Exendin-4 derivatives as dual GLP1/glucagon agonists
    Patent number: 9365632
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: June 14, 2016
    Assignee: SANOFI
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart
  • Pyrazole derivatives and their use as LPAR5 antagonists
    Patent number: 9346762
    Abstract: The present invention relates to compounds of the formula (I), wherein the residues R1 to R5, V, G and M have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses. The compounds of the invention are effective antagonists of the platelet LPA receptor LPAR5 (GPR92) and can in general be applied in conditions in which an undesired activation of the platelet LPA receptor LPAR5, the mast cell LPA receptor LPAR5 or the microglia cell LPA receptor LPAR5 is present or for the cure or prevention of which an inhibition of the platelet, mast cell or microglia cell LPA receptor LPAR5 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: May 24, 2016
    Assignee: Sanofi
    Inventors: Marc Nazare, Detlef Kozian, Andreas Evers, Werngard Czechtizky
  • Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
    Patent number: 9346757
    Abstract: The present invention relates to compounds of the formula (I), wherein the residues R1 to R6, V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses. The compounds of the invention are effective antagonists of the platelet LPA receptor LPAR5 (GPR92) and can in general be applied in conditions in which an undesired activation of the platelet LPA receptor LPAR5, the mast cell LPA receptor LPAR5 or the microglia cell LPA receptor LPAR5 is present, or for the cure or prevention of which an inhibition of the platelet, mast cell or microglia cell LPA receptor LPAR5 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: May 24, 2016
    Assignee: Sanofi
    Inventors: Marc Nazare, Detlef Kozian, Andreas Evers, Werngard Czechtizky
  • Macrocyclic Urea Derivatives as Inhibitors of TAFIa, Their Preparation and Their Use as Pharmaceuticals
    Publication number: 20160137618
    Abstract: The present invention relates to macrocydic urea derivatives of the formula I (I) in which R1, R2, R3, V and Y are as defined below. The compounds of the formula I are inhibitors of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor). The invention further relates to the process for the preparation of the compounds of formula I and to the use thereof as medicaments.
    Type: Application
    Filed: June 5, 2014
    Publication date: May 19, 2016
    Inventors: Andreas Evers, Christopher Kallus, Michael Wagner, Hermut Wehlan
  • Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
    Patent number: 9309207
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: April 12, 2016
    Assignee: SANOFI
    Inventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
  • MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA
    Publication number: 20160024033
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: July 28, 2015
    Publication date: January 28, 2016
    Inventors: Christopher KALLUS, Mark BROENSTRUP, Andreas EVERS, Anja GLOBISCH, Herman SCHREUDER, Michael WAGNER
  • Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists
    Patent number: 9221784
    Abstract: The present invention relates to compounds of the formula (I), wherein the residues A, R1 to R5, Z1 and Z2 have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses. The compounds of the invention are effective antagonists of the platelet LPA receptor LPAR5 (GPR92) and can in general be applied in conditions in which an undesired activation of the platelet LPA receptor LPAR5, the mast cell LPA receptor LPAR5 or the microglia cell LPA receptor LPAR5 is present or for the cure or prevention of which an inhibition of the platelet, mast cell or microglia cell LPA receptor LPAR5 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: December 29, 2015
    Assignee: Sanofi
    Inventors: Marc Nazare, Detlef Kozian, Martin Bossart, Werngard Czechtizky, Andreas Evers
  • Exendin-4 Derivatives as Selective Glucagon Receptor Agonists
    Publication number: 20150368311
    Abstract: The present invention relates to glucagon receptor agonists and their medical use, for example in the treatment of severe hypoglycemia.
    Type: Application
    Filed: June 12, 2015
    Publication date: December 24, 2015
    Inventors: Torsten HAACK, Siegfried STENGELIN, Andreas EVERS, Michael WAGNER, Bernd HENKEL
  • DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4
    Publication number: 20150322128
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Application
    Filed: April 6, 2015
    Publication date: November 12, 2015
    Inventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner, Dieter Kadereit
  • PEPTIDIC DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4
    Publication number: 20150322129
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists or optionally trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Application
    Filed: April 6, 2015
    Publication date: November 12, 2015
    Inventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner, Katrin Lorenz
  • Exendin-4 peptide analogues
    Patent number: 9181305
    Abstract: The present invention relates to exendin-4 peptide analogs and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: November 10, 2015
    Assignee: SANOFI
    Inventors: Torsten Haack, Andreas Evers, Michael Wagner, Bernd Henkel, Siegfried Stengelin
  • EXENDIN-4 DERIVATIVES AS PEPTIDIC DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS
    Publication number: 20150315260
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Application
    Filed: April 6, 2015
    Publication date: November 5, 2015
    Inventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner
  • Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
    Patent number: 9126955
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoaguability or fibrotic changes.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: September 8, 2015
    Assignee: SANOFI
    Inventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
  • Dual GLP-1/GIP Receptor Agonists
    Publication number: 20150166627
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Application
    Filed: December 12, 2014
    Publication date: June 18, 2015
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin
  • Dual GLP-1/Glucagon Receptor Agonists
    Publication number: 20150164997
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake
    Type: Application
    Filed: December 12, 2014
    Publication date: June 18, 2015
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart, Dieter Kadereit
  • Exendin-4 Peptide Analogues as Dual GLP-1/GIP Agonists
    Publication number: 20150164995
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake
    Type: Application
    Filed: December 12, 2014
    Publication date: June 18, 2015
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin
  • Exendin-4 Peptide Analogues
    Publication number: 20150166625
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake
    Type: Application
    Filed: December 12, 2014
    Publication date: June 18, 2015
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart, Dieter Kadereit
  • NON-ACYLATED EXENDIN-4 PEPTIDE ANALOGUES
    Publication number: 20150164996
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Application
    Filed: December 12, 2014
    Publication date: June 18, 2015
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin